Contact Us

For scientific, partnering, licensing or program enquiries, please reach out directly.

United States

Okogen, Inc.
8400 Belleview Drive, Suite 125
Plano, Texas 75024, USA

Email Us

info@okogen.com

Latest News & Press

View All News

Press Release

Okogen Announces First Patient Dosed in Phase 1/2 EMERALD Trial Evaluating Treyegen™ for Acute Infectious Conjunctivitis

November 2, 2026

Press Release

Okogen Receives CDSCO Authorization to Advance the EMERALD Phase 1/2 Study of Treyegen™ (OKG-0303) for Acute Infectious Conjunctivitis

October 6, 2026

Press Release

Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio

March 26, 2026